Cancer Biology

Small Extracellular Vesicles Promote Stiffness-mediated Metastasis

1. Alexandra Sneider
2. Ying Liu
3. Bartholomew Starich
4. Wenxuan Du
5. Praful R. Nair
6. Carolyn Marar
7. Najwa Faqih
8. Gabrielle E. Ciotti
9. Joo Ho Kim
10. Sejal Krishnan
11. Salma Ibrahim
12. Muna Igboko
13. Alexus Locke
14. Daniel M. Lewis
15. Hanna Hong
16. Michelle N. Karl
17. Raghav Vij
18. Gabriella C. Russo
19. Estibaliz Gómez-de-Mariscal
20. Mehran Habibi
21. Arrate Muñoz-Barrutia
22. Luo Gu
23. T.S. Karin Eisinger-Mathason
24. Denis Wirtz

Reviewed by preLights

The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer

1. Laura Pascual-Reguant
2. Tian V. Tian
3. Debayan Datta
4. Damiano Cianferoni
5. Savvas Kourtis
6. Antoni Gañez-Zapater
7. Chiara Cannatá
8. Queralt Serra-Camprubi
9. Lorena Espinar
10. Maria Guirola
11. Jessica Querol
12. Andrea Miró Canturri
13. Joaquin Arribas
14. Luis Serrano
15. Sandra Peiró
16. Sara Sdelci

Reviewed by Review Commons

Major data analysis errors invalidate cancer microbiome findings

1. Abraham Gihawi
2. Yuchen Ge
3. Jennifer Lu
4. Daniela Puiu
5. Amanda Xu
6. Colin S. Cooper
7. Daniel S. Brewer
8. Mihaela Pertea
9. Steven L. Salzberg

Reviewed by Arcadia Science

Mutant SF3B1 promotes malignancy in PDAC

1. Patrik Simmler
2. Eleonora I Ioannidi
3. Tamara Mengis
4. Kim Fabiano Marquart
5. Simran Asawa
6. Kjong Van-Lehmann
7. Andre Kahles
8. Tinu Thomas
9. Cornelia Schwerdel
10. Nicola Aceto
11. Gunnar Rätsch
12. Markus Stoffel
13. Gerald Schwank

• Curated by eLife

  eLife assessment

  This work examines a role for altered splicing in pancreatic tumorigenesis by interrogating effects of a specific mutation in the Sf3b splicing factor in pancreatic organoid and cell line growth primarily, with some in vivo work also performed. There is significant potential in the study but there is a concern about the lack of in vivo validation of claims that are most relevant to metastatic progression and the focus on one specific mechanism at the expense of other possible effects on splicing of factors important for disease progression.

Reviewed by eLife

TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients

1. Andrea Sacconi
2. Sara Donzelli
3. Claudio Pulito
4. Stefano Ferrero
5. Aldo Morrone
6. Marta Rigoni
7. Fulvia Pimpinelli
8. Fabrizio Ensoli
9. Giuseppe Sanguineti
10. Raul Pellini
11. Nishant Agrawal
12. Evgeny Izumchenko
13. Gennaro Ciliberto
14. Aldo Giannì
15. Paola Muti
16. Sabrina Strano
17. Giovanni Blandino

Reviewed by ScreenIT

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology

1. C. Allison Stewart
2. Carl M. Gay
3. Kavya Ramkumar
4. Kasey R. Cargill
5. Robert J. Cardnell
6. Monique B. Nilsson
7. Simon Heeke
8. Elizabeth M. Park
9. Samrat T. Kundu
10. Lixia Diao
11. Qi Wang
12. Li Shen
13. Yuanxin Xi
14. Bingnan Zhang
15. Carminia Maria Della Corte
16. Youhong Fan
17. Kiran Kundu
18. Boning Gao
19. Kimberley Avila
20. Curtis R. Pickering
21. Faye M. Johnson
22. Jianjun Zhang
23. Humam Kadara
24. John D. Minna
25. Don L. Gibbons
26. Jing Wang
27. John V. Heymach
28. Lauren Averett Byers

Reviewed by ScreenIT

Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients

1. Tom Winkler
2. Uri Ben-David

Reviewed by ScreenIT

The integration of Tgfβ and Egfr signaling programs confers the ability to lead heterogeneous collective invasion

1. Apsra Nasir
2. Sharon Camacho
3. Alec T. McIntosh
4. Garrett T. Graham
5. Raneen Rahhal
6. Molly E. Huysman
7. Fahda Alsharief
8. Anna T. Riegel
9. Gray W. Pearson

• Curated by eLife

  eLife assessment

  This represents an important study that demonstrates a high degree of heterogeneity within trailblazer cells in clusters that participate in collective migration. Solid methods highlight this heterogeneity and show that in TNBC cancers, trailblazer cells are defined by vimentin (and not Keratin 14) and are dependent on both TGFbeta and EGFR signaling.

Reviewed by eLife

Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development

1. Robbin A. Nameki
2. Heidi Chang
3. Pak Yu
4. Forough Abbasi
5. Xianzhi Lin
6. Jessica Reddy
7. Marcela Haro
8. Marcos AS Fonseca
9. Matthew L. Freedman
10. Ronny Drapkin
11. Rosario I. Corona
12. Kate Lawrenson

• Curated by eLife

  eLife assessment

  This fundamental study has successfully identified four key transcription factors (MECOM, PAX8, SOX17, and WT1) that exhibit synergistic effects and are potentially responsible for the transformation of fallopian tube secretory epithelial cells into high-grade serous 'ovarian' cancer cells. Convincing data strongly support the drawn conclusion and significantly contribute to our understanding of the etiology of this devastating cancer. The implications of this finding are substantial, as it provides molecular insights that can potentially pave the way for innovative diagnostics and therapeutics in the field of gynecological oncology. Enhancing the clarity and impact of this study would be achieved through improvements in data presentation.

Reviewed by eLife

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma

1. Wayne Croft
2. Hayden Pearce
3. Sandra Margielewska-Davies
4. Lindsay Lim
5. Samantha M Nicol
6. Fouzia Zayou
7. Daniel Blakeway
8. Francesca Marcon
9. Sarah Powell-Brett
10. Brinder Mahon
11. Reena Merard
12. Jianmin Zuo
13. Gary Middleton
14. Keith Roberts
15. Rachel M Brown
16. Paul Moss

• Curated by eLife

  eLife assessment:

  This manuscript uses an innovative combination of spatial profiling with single-cell transcriptomics to define expression profiles of stromal components in proximal tumor regions compared to those in distal regions in pancreatic ductal adenocarcinoma (PDAC). Based on this, the authors claim that the presence of a proximal fibroblast population predicts worse outcomes for PDAC patients than the presence of a distal fibroblast population. While the work provides valuable insight into how different types of tumor stromal fibroblasts may affect PDAC outcomes, the work is currently incomplete and will benefit from more extended use of fibroblast and myeloid cell markers and efforts to better define the transcriptomic data generated.

Reviewed by eLife